On December 23, the SZBL Institute of Biomedical Health Technology and Engineering convened the 2021 annual meeting. Together more than 30 institute members, participated through onsite or virtual forms, reviewed progress, took stock of past performance, and discussed future plans. Institute PIs, including Professor Ma Lan, Professor Peter E. Lobie, Professor Zhang Linqi, and Professor Chen Yuzong attended the meeting. Ma Lan presided over the meeting.

Looking back over the year 2021, the institute has yielded achievements contributed by the hard work of its every member. Highlighted here just a few:

The Sun Yongkui group, with collaborators at the Harvard Medical School and the UC Davis, has demonstrated the blocking the combination of sEH and EP4 pathways, and had the results published onPNAS;

The Peter E. Lobie group is seeing prospect of having its oral BAD phosphorylation inhibitor program moving to industrialized phase;

The Zhang Linqi group has cooperated with the Shenzhen Third People's Hospital and Brii Biosciences, and completed the development of a new covid-19 neutralizing antibody drug approved to enter the market. This is a breakthrough achievement that China, for the first time, has its own COVID-19 specific drug;

The Jiang Yuyang group has synthesized a multi-target drug dedicated to epigenetics disease, which will greatly serve the follow-up tumor microenvironment immunotherapy research;

Ma Lan's group has worked primarily on triple-negative breast cancer stem cells research. The group has also completed the sequencing analysis of induced THP-1 cell models, and of the yellow fever vaccines, immune and transcriptome sequencing;

The Xing Xinhui group focused on the development of new heparin derivatives drugs for the treatment of ulcerative colitis. The patent R&D is now joined by the CR Double-Crane Group;

The Chen Yuzong group has spent main efforts in innovating AI-based disease diagnosis application and they had established a deep learning model basing small sample omics data;

Ge Jun's group, through deepening research on enzyme-metal concerted catalysis, has contributed to an improved understanding of green chemical industry;

The Rao Lang group has developed genetically programmable fusion cellular vesicles for tumor immunotherapy, andhas submitted patent filing.

After the reports, research groups continued to discuss plans for the year 2022, in which enhanced interdisciplinary cooperation, regular meetings and workshops, and expanded original innovations were underscored.